SCHEMBL376825

SCHEMBL376825

CC(C)c1oc(-c2ccccc2Cl)nc1CCCc1ccc(OC(C)(C)C(=O)O)cc1

nearest known ligand 0.68

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.68
PPARG P37231 15/20 0.68
PPARD Q03181 8/20 0.68
NR1H4 Q96RI1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376600 0.90 PPARA (0.56) PPARAPPARGPPARDNR1H4
SCHEMBL376998 0.89 PPARG (0.65) PPARAPPARGPPARDNR1H4
SCHEMBL376724 0.86 PPARA (0.67) PPARAPPARGPPARDNR1H4
SCHEMBL377166 0.86 PPARA (0.66) PPARAPPARGPPARD
SCHEMBL376936 0.84 PPARA (0.64) PPARAPPARGPPARDNR1H4
SCHEMBL377051 0.83 PPARA (0.62) PPARAPPARGPPARD
SCHEMBL377050 0.83 PPARA (0.62) PPARAPPARGPPARD
SCHEMBL377368 0.82 PPARA (0.62) PPARAPPARGPPARD
SCHEMBL376823 0.82 PPARA (0.62) PPARAPPARGPPARD
SCHEMBL377030 0.80 PPARA (0.59) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA PPARA 3/4885PPARG 2/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.